Antisense Oligonucleotides for Neuro Indications

Bolden Therapeutics is focused on developing innovative therapies aimed at enhancing neurogenesis, the process of generating new neurons from neural stem cells, which is crucial for cognitive functions such as learning and memory. The company has identified a specific signaling pathway that can be targeted to stimulate neurogenesis, demonstrating proof-of-concept in proprietary mouse models. Their primary therapeutic approach involves the use of exon-skipping antisense oligonucleotides, which are designed to modulate this pathway and promote the formation of new brain cells. This strategy holds promise for addressing various neurological conditions, including Alzheimer’s disease, stroke recovery, treatment-resistant depression, and cognitive impairments resulting from chemotherapy or COVID-19.

The potential applications of Bolden's neurogenesis-promoting therapies are extensive, given the fundamental role of neurogenesis in brain health. The company is advancing its research with significant financial backing, including grants from the National Institutes of Health and investments from venture partners. By leveraging their foundational research from Brown University and collaborating with experienced scientists and advisors, Bolden Therapeutics aims to translate their findings into effective treatments that could significantly improve the quality of life for individuals suffering from neurological disorders.

United States

Bolden Therapeutics is a biotechnology company developing first-in-class therapeutics to treat central nervous system diseases such as Alzheimer’s and ischemic stroke. The company’s scientific founders have identified a key molecular pathway to stimulate neural stem cells to promote the birth of new neurons (neurogenesis) in the adult brain. In a proprietary mouse model Bolden has established a proof-of-concept of this approach to increase neurogenesis and enhance hippocampal-dependent memory. The company is actively developing antisense oligonucleotide and monoclonal antibody therapeutics to modulate this pathway.

Bolden Therapeutics

Company Details